NCT00553878View on ClinicalTrials.gov

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2012

Conditions

Prostate Cancer

Interventions

DRUG

Dutasteride

dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Canadian Urology Research Consortium

OTHER

NCT00553878 - Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer | Biotech Hunter | Biotech Hunter